Research Analysts Offer Predictions for FHTX FY2025 Earnings

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for Foghorn Therapeutics in a note issued to investors on Thursday, November 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.11) for the year, up from their prior forecast of ($1.15). The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.31) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at ($0.08) EPS.

Several other equities research analysts also recently issued reports on FHTX. B. Riley assumed coverage on shares of Foghorn Therapeutics in a research report on Wednesday, September 17th. They set a “buy” rating and a $10.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Foghorn Therapeutics in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Foghorn Therapeutics in a report on Wednesday, October 8th. Finally, Guggenheim began coverage on Foghorn Therapeutics in a report on Friday, November 7th. They issued a “buy” rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

Foghorn Therapeutics Stock Performance

Shares of FHTX stock opened at $4.44 on Monday. Foghorn Therapeutics has a 52 week low of $2.94 and a 52 week high of $9.33. The company’s 50 day moving average price is $4.61 and its two-hundred day moving average price is $4.78. The company has a market capitalization of $251.08 million, a P/E ratio of -3.93 and a beta of 3.02.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $8.15 million during the quarter, compared to analyst estimates of $6.20 million.

Institutional Trading of Foghorn Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Evelyn Partners Asset Management Ltd acquired a new position in Foghorn Therapeutics during the second quarter valued at approximately $33,000. Tower Research Capital LLC TRC raised its stake in shares of Foghorn Therapeutics by 136.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock worth $43,000 after purchasing an additional 5,323 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in shares of Foghorn Therapeutics during the 3rd quarter worth approximately $49,000. Persistent Asset Partners Ltd acquired a new stake in shares of Foghorn Therapeutics in the 3rd quarter valued at approximately $56,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Foghorn Therapeutics in the 3rd quarter valued at approximately $74,000. Institutional investors own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.